<p>尽管已经有了强劲的表现，<strong>RxSight, Inc.</strong>（纳斯达克代码：RXST）的股票仍在继续上涨，过去三十天上涨了 28%。然而，三十天的涨幅并没有改变长期股东在过去十二个月中股价下跌 64% 所带来的损失。</p>
<p>尽管价格有了明显反弹，但你可能仍然对 RxSight 的市销率（P/S）为 3.8 倍感到无所谓，因为美国医疗设备行业的中位市销率也接近 3.5 倍。然而，如果没有合理的基础，投资者可能会忽视一个明显的机会或潜在的挫折。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>查看我们对 RxSight 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200"/></p>
<p>纳斯达克 GM:RXST 市销率与行业比较 2025 年 12 月 12 日</p>
<h3>RxSight 最近的表现如何？</h3>
<p>RxSight 最近的收入增长与大多数其他公司相似。似乎许多人预计这种平庸的收入表现将持续下去，这使得市销率受到抑制。如果你喜欢这家公司，你会希望这种情况至少能够维持，以便在它还不太受欢迎时买入一些股票。</p>
<p>想要了解分析师对公司的估计的完整情况吗？那么我们 <strong>免费的</strong>RxSight 报告将帮助你揭示未来的趋势。</p>
<h2>收入预测与市销率是否匹配？</h2>
<p>RxSight 的市销率对于一家仅预计实现适度增长的公司来说是典型的，重要的是，它的表现与行业保持一致。</p>
<p>回顾一下，我们看到公司去年成功实现了 11% 的收入增长。最近三年期间，收入整体增长了 244%，在一定程度上得益于其短期表现。因此，可以公平地说，最近的收入增长对公司来说是非常出色的。</p>
<p>展望未来，根据跟踪该公司的十位分析师的预测，收入预计在未来三年内每年增长 3.3%。而行业预计每年将实现 136% 的增长，公司面临较弱的收入结果。</p>
<p>考虑到这一点，我们发现 RxSight 的市销率与其行业同行密切匹配令人感兴趣。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票而支付更高的价格。如果市销率降至与增长前景更一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
<h2>关键结论</h2>
<p>RxSight 似乎重新受到关注，价格的显著上涨使其市销率回归到行业其他公司的水平。然而，仅仅依靠市销率来判断是否应该出售你的股票并不明智，但它可以作为公司未来前景的实用指南。</p>
<p>我们对分析师对 RxSight 收入前景的预测的分析显示，其较差的收入前景并没有像我们预期的那样对其市销率产生负面影响。目前，我们对市销率并不乐观，因为预测的未来收入不太可能长期支持更积极的情绪。需要积极的变化来证明当前的市销率是合理的。</p>
<p>还有其他重要的风险因素需要考虑，我们发现 <strong>RxSight 有 2 个警告信号</strong>（其中 1 个让我们有些不安！），在这里投资之前你应该了解这些。</p>
<p>当然，<strong>有着良好盈利增长历史的盈利公司通常是更安全的投资</strong>。所以你可能希望查看这份 <strong>免费的</strong> 其他公司集合，这些公司有合理的市盈率并且盈利增长强劲。</p>
<p>国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是人形的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

RXST

<p>RxSight, Inc.（纳斯达克代码：RXST）在过去 30 天内股价上涨了 28%，尽管过去一年股价下跌了 64%。该公司的市销率为 3.8 倍，与行业平均水平相符，但预计年收入增长将温和，仅为 3.3%，而行业平均为 136%。如果增长未能证明当前的市销率，投资者可能会感到失望。分析师建议谨慎行事，因为增长预期有限且存在潜在风险因素</p>

<p>Despite an already strong run, <strong>RxSight, Inc.</strong> (NASDAQ:RXST) shares have been powering on, with a gain of 28% in the last thirty days. Still, the 30-day jump doesn't change the fact that longer term shareholders have seen their stock decimated by the 64% share price drop in the last twelve months.</p>
<div class="lb-trans"><p>尽管已经有了强劲的表现，<strong>RxSight, Inc.</strong>（纳斯达克代码：RXST）的股票仍在继续上涨，过去三十天上涨了 28%。然而，三十天的涨幅并没有改变长期股东在过去十二个月中股价下跌 64% 所带来的损失。</p>
</div><p>In spite of the firm bounce in price, you could still be forgiven for feeling indifferent about RxSight's P/S ratio of 3.8x, since the median price-to-sales (or &#34;P/S&#34;) ratio for the Medical Equipment industry in the United States is also close to 3.5x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.</p>
<div class="lb-trans"><p>尽管价格有了明显反弹，但你可能仍然对 RxSight 的市销率（P/S）为 3.8 倍感到无所谓，因为美国医疗设备行业的中位市销率也接近 3.5 倍。然而，如果没有合理的基础，投资者可能会忽视一个明显的机会或潜在的挫折。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>See our latest analysis for RxSight</p>
<div class="lb-trans"><p>查看我们对 RxSight 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200" alt="" original-src="https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200"/></p>
<p>NasdaqGM:RXST Price to Sales Ratio vs Industry December 12th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:RXST 市销率与行业比较 2025 年 12 月 12 日</p>
</div><h3>How Has RxSight Performed Recently?</h3>
<div class="lb-trans"><h3>RxSight 最近的表现如何？</h3>
</div><p>RxSight's revenue growth of late has been pretty similar to most other companies. It seems that many are expecting the mediocre revenue performance to persist, which has held the P/S ratio back. If you like the company, you'd be hoping this can at least be maintained so that you could pick up some stock while it's not quite in favour.</p>
<div class="lb-trans"><p>RxSight 最近的收入增长与大多数其他公司相似。似乎许多人预计这种平庸的收入表现将持续下去，这使得市销率受到抑制。如果你喜欢这家公司，你会希望这种情况至少能够维持，以便在它还不太受欢迎时买入一些股票。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on RxSight will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析师对公司的估计的完整情况吗？那么我们 <strong>免费的</strong>RxSight 报告将帮助你揭示未来的趋势。</p>
</div><h2>Do Revenue Forecasts Match The P/S Ratio?</h2>
<div class="lb-trans"><h2>收入预测与市销率是否匹配？</h2>
</div><p>RxSight's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.</p>
<div class="lb-trans"><p>RxSight 的市销率对于一家仅预计实现适度增长的公司来说是典型的，重要的是，它的表现与行业保持一致。</p>
</div><p>Taking a look back first, we see that the company managed to grow revenues by a handy 11% last year. The latest three year period has also seen an excellent 244% overall rise in revenue, aided somewhat by its short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.</p>
<div class="lb-trans"><p>回顾一下，我们看到公司去年成功实现了 11% 的收入增长。最近三年期间，收入整体增长了 244%，在一定程度上得益于其短期表现。因此，可以公平地说，最近的收入增长对公司来说是非常出色的。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 3.3% per year during the coming three years according to the ten analysts following the company. With the industry predicted to deliver 136% growth each year, the company is positioned for a weaker revenue result.</p>
<div class="lb-trans"><p>展望未来，根据跟踪该公司的十位分析师的预测，收入预计在未来三年内每年增长 3.3%。而行业预计每年将实现 136% 的增长，公司面临较弱的收入结果。</p>
</div><p>With this in mind, we find it intriguing that RxSight's P/S is closely matching its industry peers. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>考虑到这一点，我们发现 RxSight 的市销率与其行业同行密切匹配令人感兴趣。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票而支付更高的价格。如果市销率降至与增长前景更一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>关键结论</h2>
</div><p>RxSight appears to be back in favour with a solid price jump bringing its P/S back in line with other companies in the industry Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>RxSight 似乎重新受到关注，价格的显著上涨使其市销率回归到行业其他公司的水平。然而，仅仅依靠市销率来判断是否应该出售你的股票并不明智，但它可以作为公司未来前景的实用指南。</p>
</div><p>Our look at the analysts forecasts of RxSight's revenue prospects has shown that its inferior revenue outlook isn't negatively impacting its P/S as much as we would have predicted. At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long. A positive change is needed in order to justify the current price-to-sales ratio.</p>
<div class="lb-trans"><p>我们对分析师对 RxSight 收入前景的预测的分析显示，其较差的收入前景并没有像我们预期的那样对其市销率产生负面影响。目前，我们对市销率并不乐观，因为预测的未来收入不太可能长期支持更积极的情绪。需要积极的变化来证明当前的市销率是合理的。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>2 warning signs for RxSight</strong> (1 makes us a bit uncomfortable!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>还有其他重要的风险因素需要考虑，我们发现 <strong>RxSight 有 2 个警告信号</strong>（其中 1 个让我们有些不安！），在这里投资之前你应该了解这些。</p>
</div><p>Of course, <strong>profitable companies with a history of great earnings growth are generally safer bets</strong>. So you may wish to see this <strong>free</strong> collection of other companies that have reasonable P/E ratios and have grown earnings strongly.</p>
<div class="lb-trans"><p>当然，<strong>有着良好盈利增长历史的盈利公司通常是更安全的投资</strong>。所以你可能希望查看这份 <strong>免费的</strong> 其他公司集合，这些公司有合理的市盈率并且盈利增长强劲。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是人形的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

RxSight, Inc.（纳斯达克股票代码：RXST）28% 的股价上涨与其收入不相符